Impact of COVID-19 and COVID-19 vaccination on high-risk patients with antiphospholipid syndrome: a nationwide survey코로나19와 코로나19 예방접종이 항인지질증후군 고위험군 환자에 미치는 영향: 전국 조사Article Published on 2022-06-282022-09-12 Journal: Rheumatology (Oxford, England) [Category] MERS, 진단, [키워드] adverse event Adverse reaction APS Asymptomatic conducted contribute Course COVID-19 COVID-19 vaccination events high risk high-risk patient Hospitalization Impact induce injection intensive care Local MOST multicentre nine outcomes Patient patients physician potentially life-threatening progression questionnaire raised reducing reference second dose second vaccination severe COVID-19 severe disease severity Side effect Thromboembolic event thrombosis thrombotic Thrombotic complications vaccination [DOI] 10.1093/rheumatology/keac224 PMC 바로가기 [Article Type] Article
Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents건강한 청소년에서 SARS-CoV-2 백신 BNT162b2 및 CoronaVac의 면역원성 및 반응성Article Published on 2022-06-282022-09-11 Journal: Nature Communications [Category] COVID19(2023년), SARS, 변종, 임상, 치료기술, [키워드] addition Adults Adverse reaction Adverse reactions antibody Antibody Response BNT162b2 C-terminal domain cellular immunity clinical study CoronaVac dose healthy immune response immune responses immunogenicity in some induce interim analysis marker Mild myocarditis neutralising of BNT162b2 proportion reactogenicity receiving Registered risk reduction SARS-CoV-2 N SARS-CoV-2 vaccine SARS-CoV-2 vaccines Seropositivity Support T cell T cells Vaccine Vaccines [DOI] 10.1038/s41467-022-31485-z PMC 바로가기 [Article Type] Article
Safety and immunogenicity of a hybrid-type vaccine booster in BBIBP-CorV recipients in a randomized phase 2 trial무작위 2상 시험에서 BBIBP-CorV 수용자에서 하이브리드형 백신 부스터의 안전성 및 면역원성Clinical Trial Published on 2022-06-272022-09-11 Journal: Nature Communications [Category] COVID19(2023년), MERS, SARS, 변종, 임상, 진단, 치료기술, 치료법, [키워드] 1:1 Administered Adverse reaction Adverse reactions age Antigen antigens BBIBP-CorV boost booster booster dose conducted dose double-blind elicited evaluate GMT greater group healthy Heterologous homologous IgG antibodies IgG antibody immunogenic immunogenicity incidence Neutralizing and IgG antibodies neutralizing antibody omicron Omicron variant participant Phase 2 phase 2 trial Randomized receive recipient recombinant COVID-19 vaccine regimens Safe Safety safety profile SARS-CoV-2 SARS-CoV-2 strain significantly higher three groups United Arab Emirate United Arab Emirates Vaccine variant variants of concern VOCs [DOI] 10.1038/s41467-022-31379-0 PMC 바로가기 [Article Type] Clinical Trial
Safety and Immunogenicity of an Inactivated COVID-19 Vaccine, WIBP-CorV, in Healthy Children: Interim Analysis of a Randomized, Double-Blind, Controlled, Phase 1/2 Trial건강한 어린이에서 비활성화된 COVID-19 백신 WIBP-CorV의 안전성 및 면역원성: 무작위, 이중 맹검, 대조, 1/2상 시험의 중간 분석Clinical Trial Published on 2022-06-242022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, [키워드] adverse events Adverse reaction Adverse reactions age alum Antibody Response assigned children China clinical trial Cohort cohorts conducted Controlled COVID-19 COVID-19 vaccine detectable dose dose-escalation double-blind effective vaccine Effective vaccines elicited Escalation Fever followed by geometric mean geometric mean titer geometric mean titers grade 3 groups healthy children Humoral response immunogenicity inactivated Inactivated vaccine injection injection site pain Interim Intramuscular injection Mild neutralizing antibody participant phase Phase 1 phase 1 trial Phase 2 phase 2 trial Placebo placebo-controlled Randomized Randomly ranged Registered robust Safe Safety safety profile SARS-CoV-2 significantly higher tested three group three groups vaccination Vaccine [DOI] 10.3389/fimmu.2022.898151 PMC 바로가기 [Article Type] Clinical Trial
Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine항중증급성호흡기증후군 코로나바이러스 2(SARS-CoV-2) 스파이크 단백질 항체 역가 및 BNT162b2 백신 접종 후 의료 종사자의 중화 활성과 관련된 요인Observational Study Published on 2022-06-102022-09-12 Journal: PLoS ONE [Category] COVID19(2023년), MERS, SARS, 임상, 진단, [키워드] acute respiratory syndrome Adverse reaction age All participant Analysis anti-SARS-CoV-2 IgM antibody Antibody titer blood sample BNT162b2 vaccine chemiluminescent immunoassay conducted coronavirus Cutoff elevated Enrollment Factor female Fever first dose Fukushima healthcare worker hospital identify IgG IgG antibody IgG antibody titer IgM Immunoglobulin Immunoglobulin G immunosuppressive increase in individuals intake Japan joint lack Local medication N-protein Neutralizing activity Neutralizing antibody titer of BNT162b2 Pain participant Pfizer-BioNTech Prevent Protein response SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 vaccination second dose Sex significantly Spike protein the SARS-CoV-2 vaccination Vaccine vaccine doses was obtained were measured [DOI] 10.1371/journal.pone.0269917 PMC 바로가기 [Article Type] Observational Study
Efficacy and Safety of the RBD-Dimer-Based Covid-19 Vaccine ZF2001 in Adults성인에서 RBD-이량체 기반 코비드-19 백신 ZF2001의 효능 및 안전성Clinical Trial Published on 2022-06-022022-09-25 Journal: The New England Journal of Medicine [Category] COVID19(2023년), SARS, 신약개발, 임상, 진단, [키워드] 1:1 95% CI 95% confidence interval acute respiratory syndrome Adults adverse event Adverse reaction age aluminum Analysis assigned China Clinical Center clinical trials conducted coronavirus coronavirus disease Cutoff death deaths dimeric dose double-blind effective Efficacy efficacy analysis efficacy end point Follow-up hydroxide immunogenic incidence Indonesia large cohort Major MOST occurred Occurrence participant Participants phase 3 trial Placebo placebo-controlled primary end point primary end-point Randomized Randomly receive regimen reported Safe Safety safety analysis Science Serious Adverse Event shown Side-effect symptomatic technology the placebo group the receptor-binding domain Trial two groups vaccination Vaccine was performed ZF2001 [DOI] 10.1056/NEJMoa2202261 PMC 바로가기 [Article Type] Clinical Trial
Unusual contact dermatitis after SARS-CoV-2 vaccinationsArticle Published on 2022-06-012023-07-08 Journal: Contact dermatitis [Category] COVID19(2023년), [키워드] Adverse reaction Case report contact dermatitis COVID-19 frostbite SARS-CoV-2 vaccination [DOI] 10.1111/cod.14084 PMC 바로가기
Aprotinin treatment against SARS-CoV-2: A randomized phase III study to evaluate the safety and efficacy of a pan-protease inhibitor for moderate COVID-19SARS-CoV-2에 대한 아프로티닌 치료: 중등도 COVID-19에 대한 범프로테아제 억제제의 안전성과 효능을 평가하기 위한 무작위 3상 연구Clinical Trial Published on 2022-06-012022-09-11 Journal: European Journal of Clinical Investigation [Category] COVID19(2023년), SARS, 임상, 치료제, [키워드] ACE2 addition administration Adverse reaction Adverse reactions anti-inflammatory properties anti-inflammatory property antiviral drug antivirus Aprotinin cleave Clinical outcome clinical trial Composite Contact COVID-19 death discharge double-blind Efficacy evaluate follow-up period furin had no hospital Hospital admission Hospital stay Hospitalization hospitalized patient hospitalized patients host protease host proteases human respiratory viruses ICU admission IMPROVE incidence inhalation therapy inhibiting inhibitor Innate immunity less mechanism Moderate COVID-19 multicentre outcome oxygen Oxygen therapy parameter patients with COVID-19 performed placebo group Pneumonia profiles Protease inhibitor Randomized randomized trial required respiratory viruses resulting Safe Safety SARS-CoV-2 SARS-CoV-2 virus secondary endpoint Secondary endpoints Side effects significant difference significant differences Spanish Spike protein standard treatment the placebo group Treatment with COVID-19 [DOI] 10.1111/eci.13776 PMC 바로가기 [Article Type] Clinical Trial
Dynamics of anti-Spike IgG antibody level after the second BNT162b2 COVID-19 vaccination in health care workers의료 종사자의 두 번째 BNT162b2 COVID-19 예방 접종 후 항-스파이크 IgG 항체 수준의 역학Article Published on 2022-06-012022-09-12 Journal: Journal of infection and chemotherapy : official j [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] addition Adverse reaction age alcohol allergies allergy anti-Spike IgG Anti-spike IgG antibody anti-spike IgG level anti-spike IgG levels Antibody titer association BMI BNT162b2 categories correlation country COVID-19 COVID-19 vaccination COVID-19 vaccines cross-sectional dose Dynamics evaluate Fever geometric mean titer Health care worker IgG IgG antibody Japanese observation Older Older age participant remained second vaccination Sex Side effect significantly significantly lower smoking statistically significant vaccination vaccine dose Vaccine-induced immunity was performed were assessed [DOI] 10.1016/j.jiac.2022.02.024 PMC 바로가기 [Article Type] Article
Safety and immunogenicity of SARS-CoV-2 vaccines in Chinese patients with cirrhosis: a prospective multicenter study중국 간경변증 환자에서 SARS-CoV-2 백신의 안전성 및 면역원성: 전향적 다기관 연구Multicenter Study Published on 2022-06-012022-09-12 Journal: Hepatology international [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] acute respiratory syndrome Adverse Adverse reaction alanine aminotransferase ALT analyzed Child-Pugh score Child–Pugh China Chinese patient cirrhosis collected compensated compensated cirrhosis coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 vaccination COVID-19 vaccines Decompensated cirrhosis defined disease dose Elevation enrolled event Factor fatigue GRADE groups Hepatitis B virus immunogenicity inactivated independent risk factor injection site pain limit Local Mild multicenter neutralizing antibody participant Patient patients positive rate reported Safe Safety SARS-CoV-2 neutralizing antibody SARS-CoV-2 vaccine second dose serum sample severe acute respiratory syndrome coronavirus 2 systemic adverse event tested ULN vaccination Vaccine were recorded [DOI] 10.1007/s12072-022-10332-9 PMC 바로가기 [Article Type] Multicenter Study